OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry
OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry.
- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry.
- Mark is an accomplished scientific researcher and leader in the biopharmaceutical industry, with extensive experience working at the interface of medicinal and process chemistry, said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.
- Boys received his BSc from University of York (UK) and his Ph.D. in Synthetic Organic Chemistry from Colorado State University.
- OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer.